These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21848477)

  • 1. Bending the cost curve in cancer care.
    Field K; Faragher I; Gibbs P
    N Engl J Med; 2011 Aug; 365(7):675; author reply 675-6. PubMed ID: 21848477
    [No Abstract]   [Full Text] [Related]  

  • 2. Bending the cost curve in cancer care.
    Good M; Good CB
    N Engl J Med; 2011 Aug; 365(7):674-5; author reply 675-6. PubMed ID: 21848478
    [No Abstract]   [Full Text] [Related]  

  • 3. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 4. Bending the cost curve in cancer care.
    Smith TJ; Hillner BE
    N Engl J Med; 2011 May; 364(21):2060-5. PubMed ID: 21612477
    [No Abstract]   [Full Text] [Related]  

  • 5. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 7. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness in oncology.
    Rees GJ
    Lancet; 1985 Dec 21-28; 2(8469-70):1405-8. PubMed ID: 2417078
    [No Abstract]   [Full Text] [Related]  

  • 9. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis.
    Shankaran V; Jolly S; Blough D; Ramsey SD
    J Clin Oncol; 2012 May; 30(14):1608-14. PubMed ID: 22412136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer care value-learning from others.
    Gamble RB
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP139. PubMed ID: 22642284
    [No Abstract]   [Full Text] [Related]  

  • 13. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world resource use and costs of adjuvant treatment for stage III colon cancer.
    van Gils CW; de Groot S; Tan SS; Redekop WK; Koopman M; Punt CJ; Uyl-de Groot CA
    Eur J Cancer Care (Engl); 2015 May; 24(3):321-32. PubMed ID: 24372941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 16. [The economic burden of cancer and the access to innovation should boost the use of real world data].
    Thierry JP
    Bull Cancer; 2017 Jun; 104(6):495-496. PubMed ID: 28578773
    [No Abstract]   [Full Text] [Related]  

  • 17. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 19. Keynote comment: Cancer drug pricing in the USA.
    Johnson DH
    Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
    [No Abstract]   [Full Text] [Related]  

  • 20. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.